As
vobarilizumab has caught my interest a while ago [1], I had already looked
closer at this anti-IL6 receptor (IL-6R) nanobody® at the
2017 EULAR Annual Meeting in Madrid [2] and concluded: “The data is interesting
and promising, but the big question remains: will there be a phase 3 study?”
There had been one study on vobarilizumab at the 2017 ACR Annual Meeting in San
Diego, just one.
M.
Rinaldi and colleagues presented [3]: “Assessment of Dose Dependent Effects of
Vobarilizumab, an Anti-IL6 Receptor (IL-6R) Nanobody®, on Systemic Biomarkers
in Patients with Moderate-to-Severe Rheumatoid Arthritis (RA): Results of Two
Phase 2b Studies”. The authors looked at the effect of vobarilizumab and tocilizumab
on biomarkers like CRP, ESR, soluble IL-6 receptor (sIL-6R), matrix
metalloproteinase-3, and chemokine ligand 13 (CXCL13). The authors concluded: “The
observed dose dependent PD [pharmacodynamics] biomarker responses and effects
on cartilage degradation and joint inflammation biomarkers further support the
strong potential for disease modifying activity of vobarilizumab in RA
[rheumatoid arthritis].”
A
bit disappointing, isn’t it? Not the results, but the slowing down of research
and commitment. I’ve just looked, if there is a phase 3 study [4], but didn’t
find one. Abbvie seems to kindle a fire so light, that it might be blown out
soon.
Links and References:
[3]
Rinaldi M, Van Bogaert T, Van Roy M, Bontinck L, Hohlbaum A, Snoeck V,
Dombrecht E, Van Beneden K, Schoen P, Ulrichts H. Assessment of Dose Dependent
Effects of Vobarilizumab, an Anti-IL6 Receptor (IL-6R) Nanobody®, on Systemic
Biomarkers in Patients with Moderate-to-Severe Rheumatoid Arthritis (RA):
Results of Two Phase 2b Studies [abstract]. Arthritis
Rheumatol. 2017; 69 (suppl 10). http://acrabstracts.org/abstract/assessment-of-dose-dependent-effects-of-vobarilizumab-an-anti-il6-receptor-il-6r-nanobody-on-systemic-biomarkers-in-patients-with-moderate-to-severe-rheumatoid-arthritis-ra-results-of-two/ .Accessed January 13, 2018.
[4]
https://clinicaltrials.gov/ct2/results?cond=&term=ALX-0061&cntry=&state=&city=&dist=&Search=Search
.
No comments:
Post a Comment